The Methodist Hospital Research Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

Phase 2

Withdrawn

Conditions: Brain Metastases
Central Nervous System (CNS) Metastases

Interventions: Drug: Topotecan
Drug: Temozolomide

First Posted Date: 2012-11-29

Last Posted Date: 2017-09-19

Lead Sponsor: The Methodist Hospital Research Institute

Registration Number: NCT01736800

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Methodist Neurological Institute - Department of Neurosurgery, Houston, Texas, United States

MRI-Guided LITT for Treatment Metastatic Brain Tumors

Not Applicable

Withdrawn

Conditions: Brain Tumor

Interventions: Device: Visualase®

First Posted Date: 2012-11-29

Last Posted Date: 2018-01-17

Lead Sponsor: The Methodist Hospital Research Institute

Registration Number: NCT01736722

Locations: 🇺🇸
Methodist Neurological Institute - Department of Neurosurgery, Houston, Texas, United States

The Use of CoSeal (Sealant Agent) in Patients During Left Ventricular Assist Device Surgery

Not Applicable

Terminated

Conditions: Heart Failure
Ventricular Dysfunction

Interventions: Device: CoSeal
Device: BioGlue® Surgical Adhesive

First Posted Date: 2012-05-24

Last Posted Date: 2018-08-31

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 4

Registration Number: NCT01605019

Locations: 🇺🇸
The Methodist Hospital DeBakey Heart & Vascular Center, Houston, Texas, United States
🇺🇸
Texas Heart Institute, Houston, Texas, United States

Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis

Completed

Conditions: Amyotrophic Lateral Sclerosis

First Posted Date: 2012-05-07

Last Posted Date: 2012-05-07

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 267

Registration Number: NCT01592084

Locations: 🇺🇸
the Methodist Neurological Institute, Houston, Texas, United States

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

Phase 2

Completed

Conditions: Breast Neoplasms
Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Docetaxel
Drug: Abraxane
Drug: Ixabepilone

First Posted Date: 2011-10-04

Last Posted Date: 2023-01-23

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 38

Registration Number: NCT01446016

Locations: 🇺🇸
Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
🇺🇸
Houston Methodist Hospital Cancer Center, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital Willowbrook, Houston, Texas, United States

A Trial of Esophageal and Gastric Stenting for Leak or Perforation

Phase 2

Completed

Conditions: Esophageal or Gastric Perforations
Esophageal or Gastric Leaks

Interventions: Device: Boston Scientific Ultraflex or Wallstent stents

First Posted Date: 2010-04-20

Last Posted Date: 2016-03-17

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 10

Registration Number: NCT01107249

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ixabepilone
Drug: Cetuximab

First Posted Date: 2010-04-01

Last Posted Date: 2021-09-22

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 40

Registration Number: NCT01097642

Locations: 🇺🇸
The Methodist Hospital Cancer Center, Houston, Texas, United States

Safety of Riluzole in Patients With Acute Spinal Cord Injury

Completed

Conditions: Spinal Cord Injury

First Posted Date: 2009-04-07

Last Posted Date: 2017-09-12

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 36

Registration Number: NCT00876889

Locations: 🇺🇸
The University of Texas, Houston, Texas, United States
🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸
University of Louisville Health Sciences Center, Louisville, Kentucky, United States

and more 5 locations

Adrenal Insufficiency in Septic Shock

Phase 4

Terminated

Conditions: Septic Shock
Acute Adrenal Insufficiency

Interventions: Drug: Corticosteroid

First Posted Date: 2009-02-12

Last Posted Date: 2011-06-29

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 32

Registration Number: NCT00842933

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

Phase 2

Withdrawn

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Vorinostat in combination with Bortezomib

First Posted Date: 2009-02-05

Last Posted Date: 2017-09-19

Lead Sponsor: The Methodist Hospital Research Institute

Registration Number: NCT00837174

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy